Trial Profile
Roflumilast as additional therapy to long-acting beta-adrenoceptor agonists (LABA) + long-acting antimuscarinic agent (LAMA) + inhaled corticosteroids (ICS) in patients with severe chronic obstructive pulmonary disease(COPD).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Nov 2014
Price :
$35
*
At a glance
- Drugs Roflumilast (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Takeda
- 13 Nov 2014 New trial record